GU Cancers 2019 | First-line therapy options for RCC: lessons from CheckMate 214 and KEYNOTE-427

Michael Atkins

Michael Atkins, MD, of Georgetown University, Washington, DC, gives an overview of the first-line therapy options for patients with intermediate or poor-risk renal cell carcinoma (RCC). Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Atkins summarizes the promising results from the CheckMate 214 trial (NCT02231749), where the combination of nivolumab plus ipilimumab demonstrated superior efficacy compared to sunitinib, and the KEYNOTE-427 study (NCT02853344) looking at the efficacy of pembrolizumab therapy in RCC.

Share this video